RxDoctor Payments Data

Christopher Louck, MD

Family Medicine · Rensselaer, INNPI 1134266190

Payments from drug & device makers

$1,240in general payments, 2019–2025

Across 92 payments — averaging $13.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$326
  • Pfizer$138
  • Johnson & Johnson$128
  • AstraZeneca$116
  • Takeda Pharmaceuticals U.S.A., Inc.$103
  • Novartis$88
  • plus $341 from 9 others

What the payments were for

  • Food & beverage$1,240100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,240 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$161,627
Medicare patients
432
Services billed
3,598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban128$164,229
OzempicSemaglutide74$127,895
XareltoRivaroxaban57$65,727
JardianceEmpagliflozin36$51,865
TrulicityDulaglutide53$50,805
EntrestoSacubitril/Valsartan21$34,463
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$33,293
FarxigaDapagliflozin Propanediol23$28,589
JanuviaSitagliptin Phosphate15$24,174
Fondaparinux Sodium13$18,573
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$15,568
Spiriva RespimatTiotropium Bromide22$14,451
Breo ElliptaFluticasone/Vilanterol16$12,880
Janumet XrSitagliptin Phos/Metformin Hcl15$12,148
Lantus SolostarInsulin Glargine,hum.Rec.Anlog67$11,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$138$169,650146 claims
Novo NordiskOzempic$13$127,89574 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Stiolto Respimat$64$84,30487 claims
Johnson & JohnsonXarelto$128$65,72757 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$13$65,004103 claims
Lilly USA, LLCTrulicity$81$50,80553 claims
MerckJanuvia, Janumet Xr$11$36,32230 claims
NovartisEntresto$88$34,46321 claims
AstraZenecaFarxiga, Symbicort$116$32,32440 claims
AbbVieSynthroid$71$3,24144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Rensselaer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →